Sagrada of the tab. of p/o of 10 mg No. 28

Which tablets Sagrada is a part prasugrel, in combination with acetylsalicylic acid (ASK) is shown for prevention of aterotrombotichesky events at adult patients with a sharp coronary syndrome, that is the unstable stenocardia (US), a myocardial infarction without raising of a segment of ST (YIM BP of ST) or a myocardial infarction with raising of a segment of ST (YIM ZP of ST) which carries out primary or delayed percutaneous coronary intervention (PCI).

Structure

Active ingredient: prasugrel.

1 tablet contains prasugrel 10 mg.

Excipients: krospovidon (type A), lactose monohydrate, sodium of a kroskarmelloz, cellulose microcrystalline (E460), sucrose stearate.

Contraindication

Hypersensitivity to active ingredient or to any of medicament excipients.

Active bleeding.

Stroke or the tranzitorny ischemic attack (TIA) in the anamnesis.

Heavy liver failure (class C on Chayld-Pyyu).

Reception prasugret

begin 60 mg with single dose of a load dose. Further daily accept a maintenance dose of 10 mg. Patients with NANOSECOND / YIM of BP ST which carries out a coronary angiography a course of 48 hours after hospitalization have to accept a load dose only during ChKV. The patients accepting prasugrel also have to accept daily ASK (75-325 mg/days).

premature termination of therapy by any antiagregant, including prasugrel, can result

At patients with Construction Department which carried out ChKV in the increased risk of thrombosis, myocardial infarction or death owing to a basic disease. It is recommended to continue treatment up to 12 months if there are no indications for cancellation prasugret.

Medicine in this dosage is not applied by

to patients aged from 75 years.

Medicine in this dosage is not applied by

to patients with body weight less than 60 kg.

Feature of use

Pregnant women

Research on animals did not reveal direct negative impact on a pregnancy course, embryonic or post-natal development. Prasugrel it is possible to appoint during pregnancy, only if the potential advantage for mother exceeds potential risk for a fruit.

Children

Use of medicament for children and teenagers aged up to 18 years contraindicated.

Drivers

it is not established influences prasugrelya on ability to run vehicles and mechanisms.

Overdose

Symptoms: increase in a bleeding time and the complications connected with it is possible.

is not present, however, if urgent reduction of a bleeding time is required, transfusion of platelet concentrate and/or other blood preparations can be carried out.

Safety at the patients with a sharp coronary syndrome who transferred ChKV was estimated by

in one controlled klopidogrely research (TRITON) in which 6741 patients received prasugrel (60 mg of a load dose and 10 mg of 1 times a day to a maintenance dose) on average within 14 5 months (5802 patients were treated more than 6 months, 4136 patients were treated more than 1 year). Frequency of cancellation of the studied medicament through the undesirable phenomena was 7.2% for prasugrel and 6.3% for klopidogrelya. Bleeding was widespread side reaction for both medicaments that led to the termination of administration of medicament (2.5% for prasugrel and 1.4% for klopidogrelya).

Interaction

Warfarin. Simultaneous use prasugrelya with coumarin derivatives, except warfarin, was not studied. For potentially increased risk of bleedings and prasugrel it is necessary to appoint warfarin (or other derivatives of coumarin) with care.

to Store

in original packing at a temperature up to 25 °C. To store out of children's reach.

Expiration date - 3 years.